Theranostics
Recurrent Prostate Cancer
Authors:
Lenzo Nat, BSc BMedSci(Hons) MBBS MSc(Oncol) MMed MHSvMgt EMBA FRACP FAANMS GAICD
, Lim Tee, MBBS, FRANCR
,
Sohi J.S
Journal: Appl Radiol, volume: Jul/Aug, pages 40-43
Year: 2021
Theranostics
Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments
Authors:
Andrea Farolfi; Wolfgang Fendler; Amir Iravani; Uwe Haberkorn; Rodney Hicks; Ken Herrmann; Jochen Walz; Stefano Fanti
Journal: Eur Urol Oncol, volume: Mar;2(2), pages 152-162
Year: 2019
Theranostics
Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer
Authors:
Heck M; Tauber R; Schwaiger S et al.;
Year: 2018
Theranostics
[177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Authors:
Michael S Hofman; John Violet; Rodney J Hicks; Justin Ferdinandus; Sue Ping Thang; Tim Akhurst; Amir Iravani; Grace Kong; Aravind Ravi Kumar; Declan G Murphy; Peter Eu; Price Jackson; Mark Scalzo; Scott G Williams; Shahneen Sandhu
Journal: The Lancet Oncology, volume: Jun; 19(6), pages 825-833
Year: 2018
Theranostics
Current status of theranostics in prostate cancer
Authors:
Virgolini I; Decristoforo C; Haug A et al.
Journal: Current status of theranostics in prostate cancer
Year: 2017